Ikena Oncology Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Mark Manfredi
Algemeen directeur
US$1.2m
Totale compensatie
| Percentage CEO-salaris | 45.9% |
| Dienstverband CEO | 6.9yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 1.1yrs |
| Gemiddelde ambtstermijn bestuur | 4yrs |
Recente managementupdates
Recent updates
Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)
Jun 01
Growth Investors: Industry Analysts Just Upgraded Their Ikena Oncology, Inc. (NASDAQ:IKNA) Revenue Forecasts By 31%
Nov 10Analysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS Numbers
Aug 15Need To Know: Analysts Are Much More Bullish On Ikena Oncology, Inc. (NASDAQ:IKNA) Revenues
May 20Will Ikena Oncology (NASDAQ:IKNA) Spend Its Cash Wisely?
Apr 29We Think Ikena Oncology (NASDAQ:IKNA) Needs To Drive Business Growth Carefully
Jan 06Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth
Aug 06Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts
Mar 23Ikena Oncology, Inc. (NASDAQ:IKNA) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 21Is Ikena Oncology (NASDAQ:IKNA) In A Good Position To Deliver On Growth Plans?
Feb 19We're Not Very Worried About Ikena Oncology's (NASDAQ:IKNA) Cash Burn Rate
Nov 02Ikena Oncology (NASDAQ:IKNA) Is In A Good Position To Deliver On Growth Plans
Jul 13Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$67m |
| Mar 31 2024 | n/a | n/a | -US$70m |
| Dec 31 2023 | US$1m | US$569k | -US$68m |
| Sep 30 2023 | n/a | n/a | -US$63m |
| Jun 30 2023 | n/a | n/a | -US$63m |
| Mar 31 2023 | n/a | n/a | -US$66m |
| Dec 31 2022 | US$2m | US$546k | -US$69m |
| Sep 30 2022 | n/a | n/a | -US$52m |
| Jun 30 2022 | n/a | n/a | -US$49m |
| Mar 31 2022 | n/a | n/a | -US$41m |
| Dec 31 2021 | US$5m | US$530k | -US$34m |
| Sep 30 2021 | n/a | n/a | -US$63m |
| Jun 30 2021 | n/a | n/a | -US$55m |
| Mar 31 2021 | n/a | n/a | -US$47m |
| Dec 31 2020 | US$606k | US$410k | -US$44m |
Compensatie versus markt: De totale vergoeding ($USD 1.24M ) Mark } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 655.02K ).
Compensatie versus inkomsten: De vergoeding van Mark is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Mark Manfredi (53 yo)
6.9yrs
Tenure
US$1,240,640
Compensatie
Dr. Mark Manfredi, Ph D., serves as Member of Scientific Advisory Board of Bantam Pharmaceutical, LLC. He has been President, Chief Executive Officer and Director of Ikena Oncology, Inc. since December 201...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 6.9yrs | US$1.24m | geen gegevens | |
| CFO & Head of Corporate Development | 2.6yrs | US$782.32k | 0% $ 0 | |
| Vice President of Investor Relations | less than a year | geen gegevens | geen gegevens | |
| Chief Development Officer | 3yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Finance & Operations | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Clinical Development Operations | 1.1yrs | geen gegevens | geen gegevens | |
| Chief Medical Officer | less than a year | geen gegevens | geen gegevens | |
| Senior Vice President of Technical Operations | less than a year | geen gegevens | geen gegevens |
1.1yrs
Gemiddelde duur
52.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van IKNA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.1 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 6.9yrs | US$1.24m | geen gegevens | |
| Independent Director | 8.7yrs | US$130.36k | 0% $ 0 | |
| Chair of Scientific Advisory Board | 4yrs | geen gegevens | geen gegevens | |
| Independent Director | 3.9yrs | US$128.25k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 4yrs | geen gegevens | geen gegevens | |
| Chairman of the Board | 1.8yrs | US$167.86k | 0% $ 0 | |
| Independent Director | 8.7yrs | US$131.86k | 0% $ 0 | |
| Independent Director | 8yrs | US$126.97k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$117.86k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4yrs | geen gegevens | geen gegevens | |
| Independent Director | 3.6yrs | US$117.86k | 0% $ 0 |
4.0yrs
Gemiddelde duur
62.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van IKNA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).